ReVision Implant, a Belgian neurotechnology startup, announced on Mar. 9 that it has received Breakthrough Device designation from the U.S. Food and Drug Administration for its Occular visual cortical prosthesis. This designation paves the way for first-in-human clinical trials of the device.
The Occular system is intended to restore functional vision in people with severe blindness, including those who cannot benefit from retinal implants or optic nerve therapies. The technology stands out because it interfaces directly with the brain’s visual cortex, bypassing damage to the eye or optic nerve.
The system works by using a miniature camera mounted on a wireless headset to capture visual information. This data is then transmitted to a brain implant that stimulates neurons in patterns interpreted by the brain as points of light, forming simple visual representations that may help users identify objects and navigate their surroundings.
Development of Occular began in 2020, and ReVision Implant reports extensive preclinical testing, including long-term animal studies lasting more than two years. The company has focused on ensuring long-term performance from the outset.
Receiving Breakthrough Device status allows ReVision Implant early feedback on regulatory roadmaps and access to the FDA’s Total Product Life-Cycle Advisory Program Pilot. Only 160 medical devices received this status throughout 2025, highlighting the selectivity of this recognition.
A short-term clinical trial during scheduled brain surgery is planned for October 2026, with early-stage human clinical trials in blind volunteers expected as soon as summer 2027, pending regulatory approvals. Frederik Ceyssens, CEO of ReVision Implant said: “While cochlear implants have transformed treatment for hearing loss, there is still no widely available neuroprosthetic solution for restoring vision.”
“Our aim is to provide people living with severe blindness with functional vision that improves independence and quality of life,” Ceyssens said.
Globally, tens of millions live with severe vision loss that current surgical or pharmaceutical approaches cannot treat. Because Occular stimulates the visual cortex directly, it may be suitable for patients with various causes of blindness such as retinal degeneration and optic nerve damage. If successful in clinical trials, ReVision Implant believes its system could benefit about 650,000 patients with untreatable blindness in the US and EU combined.
